Live Feeds
● LIVE Updated 1h ago · 9 sources tracked

Women travel thousands of miles for a reproductive moonshot. Scientists say they've been misled

International Fertility Group of North America has paused marketing mitochondrial replacement therapy for age-related infertility following a STAT investigation. The probe found that a technique designed to prevent mitochondrial disease inheritance is being sold globally as a fertility treatment for older women despite limited evidence of its effectiveness. Some women paid a U.S. broker between $20,000 and $30,000 to access these overseas procedures. Scientists warn that patients have been misled about the benefits of this experimental approach.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (9)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Mitochondrial replacement therapy was developed to prevent the inheritance of mitochondrial disease.
  • ✓ A U.S. broker charged older women $20,000 to $30,000 for overseas three-parent IVF.
  • ✓ International Fertility Group of North America paused marketing MRT for age-related infertility after a STAT investigation.
  • ✓ New data from the UK raise questions about the risks associated with MRT.
🛡️ Source Corroboration: 9 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

International Fertility Group of North America paused marketing MRT for age-related infertility after a STAT investigation.

Live updates

  1. Investigation reveals MRT sold as unproven fertility treatment for older women

    International Fertility Group of North America has paused marketing mitochondrial replacement therapy for age-related infertility following a STAT investigation. The probe found that a technique designed to prevent mitochondrial disease inheritance is being sold globally as a fertility treatment for older women despite limited evidence of its effectiveness. Some women paid a U.S. broker between $20,000 and $30,000 to access these overseas procedures. Scientists warn that patients have been misled about the benefits of this experimental approach.

    Why it matters

    Mitochondrial replacement therapy, often called three-parent IVF, was developed to stop the inheritance of mitochondrial diseases. Its application for age-related infertility remains experimental and lacks robust evidence. This shift in marketing creates significant safety and ethical concerns for women seeking pregnancy.

    What is confirmed

    • Mitochondrial replacement therapy was developed to prevent the inheritance of mitochondrial disease.
    • A U.S. broker charged older women $20,000 to $30,000 for overseas three-parent IVF.
    • International Fertility Group of North America paused marketing MRT for age-related infertility after a STAT investigation.
    • New data from the UK raise questions about the risks associated with MRT.

    Still unconfirmed

    • Fertility clinics are running experiments on desperate women.

    What to watch next

    • Further release of UK data regarding MRT safety risks.
    • Regulatory responses to the marketing of MRT for non-disease indications.
    Sources used for this update (12)
    1. STAT — Women travel thousands of miles for a reproductive moonshot. Scientists say they've been misled
    2. STAT — ‘Three-parent IVF’ was supposed to prevent mitochondrial disease. Studies are raising doubts
    3. Medical Daily — Older Women Paid a U.S. Broker $20,000 to $30,000 for Overseas Three-Parent IVF Despite Little Evidence It Helps
    4. ua.news — New data from the UK raise questions about MRT risks — STAT News
    5. STAT — A STAT reporter on covering MRT as an experimental fertility treatment
    6. Tech Times — Three-Parent IVF Safety Crisis Deepens: US Broker Charged Women $30,000 for Unproven Procedure
    7. www.statnews.com — Women travel thousands of miles for a reproductive moonshot ...
    8. rocketnews.com — Women travel thousands of miles for a reproductive moonshot ...
    9. www.clinicalobserver.com — Fertility firm pauses marketing of 'three-parent IVF' after ...
    10. evagene.com — Investigation finds mitochondrial replacement therapy ...
    11. evagene.com — Studies raise safety and efficacy questions over MRT marketed ...
    12. botonomous.ai — Women travel thousands of miles for a reproductive moonshot ...
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community